BioPharma Resources

Drug Trial Radar · NCT04811040

Study to Evaluate the Safety and Efficacy of Teropavimab and Zinlirvimab in Combination With Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection

A Phase 1b Randomized, Blinded, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Broadly Neutralizing Antibodies (bNAbs) GS-5423 and GS-2872 in Combination With Capsid Inhibitor Lenacapavir (GS-6207) in Virologically Suppressed Adults With HIV-1 Infection

Last checked: Nov 19, 2026Latest source record: Jan 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

32

Actual

Start

Apr 8, 2021

Primary completion

Jun 9, 2022

Study completion Oct 26, 2023

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Mar 23, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the safety and tolerability of a combination of the broadly neutralizing antibodies (bNAbs) teropavimab (formerly GS-5423) and zinlirvimab (formerly GS-2872) in combination with the HIV capsid inhibitor lenacapavir (LEN).

Conditions

  • HIV-1 Infection

Interventions

  • Oral LenacapavirDrug

    Tablets administered without regard to food

  • Subcutaneous LenacapavirDrug

    Administered in the abdomen via subcutaneous injections

  • TeropavimabDrug

    Administered intravenously

  • ZinlirvimabDrug

    Administered intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Cohort: Percentage of Participants Experiencing Treatment-Emergent Serious Adverse Events (SAEs)Time frame: Day 1 up to Week 26

Locations

23 sites in 1 country. Site status is shown where the registry gives one.

  • Ruane Clinical Research Group Inc.

    Los Angeles, California

  • Mills Clinical Research

    Los Angeles, California

  • One Community Health

    Sacramento, California

  • UCSD AntViral Research Center (AVRC)

    San Diego, California

  • Yale University; School of Medicine; AIDS Program

    New Haven, Connecticut

  • Midway Immunology and Research Center

    Ft. Pierce, Florida

  • University of Miami Miller School of Medicine Schiff Center for Liver Disease

    Miami, Florida

  • Orlando Immunology Center

    Orlando, Florida

  • Triple O Research Institute, P.A

    West Palm Beach, Florida

  • Mercer University, Department of Internal Medicine

    Macon, Georgia

  • Indiana CTSI Clinical Research Center

    Indianapolis, Indiana

  • National Institutes of Health/Clinical Center

    Bethesda, Maryland

  • Be Well Medical Center

    Berkley, Michigan

  • AXCES Research Group

    Santa Fe, New Mexico

  • Icahn School of Medicine at Mount Sinai-Clinical and Translational Research Center

    New York, New York

  • NC TraCS Institute-CTRC; University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina

  • The Brody School of Medicine at East Carolina University, ECU Adult Specialty Care

    Greenville, North Carolina

  • Rosedale Health & Wellness

    Huntersville, North Carolina

  • Perelman Center for Advanced Medicine at the Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania

  • St. Jude Children's Research Hospital

    Memphis, Tennessee

  • Central Texas Clinical Research

    Austin, Texas

  • The Crofoot Research, INC.

    Houston, Texas

  • Peter Shalit, M.D.

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.